FDA Clearance Tracker · P100026-S101
NeuroPace® RNS® System
Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this decision)Source: openFDAMethods & limitations
Decided
May 28, 2026
Approved
Time to decision
295 days
Received Aug 6, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P100026-S101
- Device name
- NeuroPace® RNS® System
- Applicant
- NeuroPace, Inc.
- Applicant location
- Mountain View, CA
- Received
- Aug 6, 2025
- Decided
- May 28, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P100026
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
approval for an optional Electrocorticogram (ECoG) Assistant function, which is a clinician tool that highlights ECoG recordings of interest, for the Patient Data Management System.
Source documents
Other decisions for NeuroPace, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.